-
Gabriel Leventhal
CSOPharmaBiome -
Pedro Correa de Sampaio
CEONeobe Therapeutics -
Romain Daillere
Head of Preclinical Research, Co-FounderEverimmune -
Jean-Luc Marsat
CEOEverimmune -
Aaron Cowley, Ph.D., MBA
Chief Scientific OfficerReciBioPharm -
Benjamin Hadida
Chief Executive OfficerExeliom Biosciences -
Osnat Tirosh
Head of Microbiome Research and InnovationBiomica -
Juan Basterra
CEOMikrobiomik -
Shahram Lavasani
CEOImmuneBiotechDr. Shahram Lavasani is an international keynote speaker and entrepreneur in the field of the microbiome. He received his PhD in Immunology from Lund University/Sweden. With more than two decades of teaching and research expertise on Gut-Brain axis, he has pioneered research in multiple sclerosis by demonstrating gut inflammation and barrier dysfunction and introduced microbiota-based therapies using probiotic bacterial consortia. He is the founder of ImmuneBiotech developing novel microbiome therapeutics. The company has access to a proprietary lactobacilli library and advanced selection technologies to design nutritional formulations for optimal management of the diseases. ImmuneBiotech´s first product GutMagnific® has been designed to address the underlying causes of IBS and it is currently investigated, in collaboration with Karolinska Institute, for treatment of chronic fatigue syndrome (ME/CFS) a neuroimmune condition and a possible long-term effect of Covid-19. GutMagnific® has successfully been launched in October 2019.
-
Eric Van der Helm
VP Scientific Affairs, Bioinformatics & AutomationSNIPR Bio -
Anna Chwalibog
CEO, Co-founderIntegral Solutions -
Evelina Vågesjö, PhD MBA
CEOIlya PharmaCo-founder of and developed the concept during PhD 2011-2016, is now CEO and heading the drug and business development in Ilya Pharma. Also BSc in Management Accounting and finished an MBA 2018. Raised >4.3 M€ in grant funding to the project, lead the first private share issue in 2017 and designed stock option programs for key employees.
-
Nathalie Corvaia
CSOMaaT Pharma -
Chrysi Sergaki
Microbiome Group LeaderMHRA -
Steve Emery
CSOChain Biotech -
Sarah Lebeer
ProfessorUniversity of Antwerp -
Ruben Vazquez Uribe
Co-principal InvestigatorNovo Nordisk Foundation Center for Biosustainability -
Adam Baker
Director of SciencesChr. Hansen -
Harriet Schellekens
LecturerUniversity College Cork -
Pilar Manrique Ronquillo
Research ScientistMicroviable Tx -
Rosanne Hertzberger
PIVrije Universiteit Amsterdam -
Lothar Steidler
CTOActoBio Tx -
Jonathan Swann
ProfessorUniversity of Southampton -
Selin Bolca
Head of DevelopmentMRM Health -
Johan E.T. van Hylckama Vlieg
Chief Scientific OfficerFreya Biosciences -
Christophe Roca
Pilot Plant ManagerSacco Systems -
Stella Ackrell
VP, Pharmaceutical DevelopmentDestiny Pharma